BONIVA Injection Reimbursement and Coding

Site Map

FAQ

Printer Friendly Version

Healthcare Professional Home Page

About BONIVA Tablets

About BONIVA Injection

Efficacy

Tolerability

Dosing

Reimbursement & Coding

Prescribing Information

Information for Patients

BONIVA One tablet. Once a month.

Reimbursement and Coding

Coding

BONIVA Injection is eligible for Part B drug coverage
All claims must include an accurate ICD-9-CM diagnosis code
Commercial insurers, Medicare and many Medicaid agencies require an HCPCS^† code from reimbursement brochure

Please download our coding and reimbursement information for details on code type and description as well as straightforward steps to drug acquisition.

Here to help you every step of the way

Contact the BONIVA Reimbursement Hotline at
1-888-587-9438 (Monday-Friday, 9:00 AM to 7:00 PM ET)
The BONIVA Reimbursement Hotline will assist you with^‡:
- Coding/billing information
- Coverage details

*The coding, coverage and payment information contained herein is gathered from various resources and is subject to change without notice. Roche and GSK cannot guarantee success in obtaining third-party insurance programs. Third-party payment for medical products and services is affected by numerous factors. It is always the provider’s responsibility to determine and submit appropriate codes, charges and modifiers for services that are rendered. Providers should contact their third-party payers for specific information on their coding, coverage and payment policies.

^†HCPCS: Healthcare Common Procedure Coding System.

^‡The BONIVA Reimbursement Hotline does not file appeals for callers or guarantee success in obtaining insurance payments.

Read full Prescribing Information.

Important Safety Information for BONIVA Injection
BONIVA Injection is contraindicated in patients with uncorrected hypocalcemia or known hypersensitivity to BONIVA Injection or any of its excipients. BONIVA Injection, like other bisphosphonates administered intravenously, may cause a transient decrease in serum calcium values. Hypocalcemia, hypovitaminosis D, and other disturbances of bone and mineral metabolism must be effectively treated before starting therapy. Patients must receive supplemental calcium and vitamin D. BONIVA Injection must only be administered intravenously by a healthcare professional. Patients who receive BONIVA Injection should have serum creatinine measured prior to each dose. BONIVA Injection should not be administered to patients with severe renal impairment (creatinine clearance <30 mL/min). Rarely, patients have reported severe bone, joint and/or muscle pain after taking bisphosphonate therapy for osteoporosis. Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures who received intravenous bisphosphonates.

In a one-year study comparing BONIVA Injection 3 mg quarterly and BONIVA Tablets 2.5 mg daily, the overall safety and tolerability profiles with the two dosing regimens were similar. The most commonly reported adverse events (≥5%) regardless of causality were arthralgia (9.6% BONIVA Injection vs 8.6% BONIVA Tablet 2.5 mg), back pain (7.0% vs 7.5%), hypertension (5.3% vs 7.1%), abdominal pain (5.1% vs 5.6%), influenza (4.7% vs 8.0%) and nasopharyngitis (3.4% vs 6.0%). In some patients acute phase reaction-like events (10% BONIVA Injection vs 4% BONIVA Tablet) have been reported within 3 days of an IV dose and lasting for 7 days or less, most commonly after the first injection. In most cases, no specific treatment was required and symptoms subsided in 24-48 hours.

GlaxoSmithKline